We are live on ! Find out more
JANX icon

Janux Therapeutics
JANX

121 hedge funds and large institutions have $1.59B invested in Janux Therapeutics in 2024 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 24 increasing their positions, 29 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

950% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 6

342% more capital invested

Capital invested by funds: $360M → $1.59B (+$1.23B)

89% more funds holding

Funds holding: 64 → 121 (+57)

9.24% more ownership

Funds ownership: 72.71% → 81.95% (+9.2%)

17% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 29

43% less call options, than puts

Call options by funds: $3.76M | Put options by funds: $6.66M

Holders
121
Holders Change
+57
Holders Change %
+89.06%
% of All Funds
1.74%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
63
Increased
24
Reduced
29
Closed
6
Calls
$3.76M
Puts
$6.66M
Net Calls
-$2.9M
Net Calls Change
-$2.94M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$67M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$30.9M
3
RI
RTW Investments
New York
+$21.8M
4
O
OrbiMed
New York
+$20.9M
5
CAM
Cormorant Asset Management
Massachusetts
+$16.3M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$36.2M
2
Citadel Advisors
Citadel Advisors
Florida
-$16.8M
3
SB
Samsara BioCapital
California
-$3.92M
4
BlackRock
BlackRock
New York
-$1.48M
5
Millennium Management
Millennium Management
New York
-$1.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
LGM
26
Logos Global Management
California
$5.65M +$3.27M +150,000 New
SC
27
Stempoint Capital
New York
$4.58M +$2.65M +121,642 New
Morgan Stanley
28
Morgan Stanley
New York
$4.56M -$298K -13,665 -10%
RPAM
29
Rhenman & Partners Asset Management
Sweden
$3.93M +$2.28M +104,500 New
Renaissance Technologies
30
Renaissance Technologies
New York
$3.5M +$2.02M +92,899 New
Two Sigma Advisers
31
Two Sigma Advisers
New York
$3.12M +$1.29M +59,400 +252%
CS
32
Candriam SCA
Luxembourg
$3.01M +$1.74M +80,005 New
N
33
Nuveen
North Carolina
$2.96M -$64.2K -2,949 -4%
ACM
34
Atika Capital Management
New York
$2.43M +$1.4M +64,500 New
Macquarie Group
35
Macquarie Group
Australia
$2.26M +$1.31M +60,000 New
EI
36
EAM Investors
California
$2.11M +$1.22M +55,973 New
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$2.06M +$1.19M +54,638 New
Capstone Investment Advisors
38
Capstone Investment Advisors
New York
$1.97M +$1.14M +52,300 New
AG
39
Artal Group
Luxembourg
$1.88M +$1.09M +50,000 New
DekaBank Deutsche Girozentrale
40
DekaBank Deutsche Girozentrale
Germany
$1.88M – – –
Charles Schwab
41
Charles Schwab
California
$1.85M +$67.9K +3,117 +7%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$1.83M -$88.4K -4,059 -8%
AGP
43
Artia Global Partners
Florida
$1.81M +$1.04M +47,949 New
Squarepoint
44
Squarepoint
New York
$1.62M -$392K -18,017 -29%
Citigroup
45
Citigroup
New York
$1.57M +$822K +37,745 +986%
ZIM
46
Zacks Investment Management
Illinois
$1.54M -$389K -17,885 -30%
VOYA Investment Management
47
VOYA Investment Management
Georgia
$1.53M +$885K +40,653 New
LCM
48
Laurion Capital Management
New York
$1.51M +$871K +40,000 New
OCM
49
Ovata Capital Management
Hong Kong
$1.51M +$871K +40,000 New
Swiss National Bank
50
Swiss National Bank
Switzerland
$1.2M – – –
1
2
3 4 5

JANX Hedge Fund Activity: Q1 2024 in Review

121 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q1 2024, worth a combined $1.59B — up 342% from $360M a quarter earlier.

Buyers outnumbered sellers: 63 funds opened new JANX positions and 6 closed out — a net gain of 57 holders — while 24 added to existing stakes and 29 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $67M. The largest seller was BVF Inc, cutting an estimated $36.2M.

  • 121 institutional investors held Janux Therapeutics (JANX) as of Q1 2024, up from 64 in Q4 2023.
  • Funds reported $1.59B of Janux Therapeutics stock for Q1 2024, up 342% quarter-over-quarter.
  • 63 funds opened new Janux Therapeutics positions in Q1 2024 and 6 closed out, a net change of +57 holders.
  • The largest Janux Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $67M added.
  • The largest Janux Therapeutics seller in Q1 2024 was BVF Inc, an estimated $36.2M sold.

Based on aggregated 13F filings for Q1 2024.